Following the presentation of the SURViV trial in the Late Breaking Clinical Trials sessions at the American College of Cardiology Congress, Dr. Dimytri Siqueira (Brazil), principal investigator of the study, spoke exclusively with SOLACI about the results, scope, and clinical implications of this research.
The virtual event also featured the participation of a SOLACI panel composed of Dr. Ricardo Costa (Brazil, President of SOLACI), Dr. Aníbal Damonte (Argentina, former President of SOLACI), and Dr. Jorge Sandoval (Chile, interventional cardiologist), who joined the final interactive discussion.
The SURViV Trial is a prospective, randomized Latin American study conducted at 7 centers in Brazil, aimed at comparing the clinical outcomes of a novel mitral valve replacement surgery versus transseptal transcatheter mitral Valve-in-Valve treatment. Its findings have a significant impact on clinical practice and provide valuable insights in this field.
This event is part of the special scientific coverage that SOLACI is developing on the key highlights of ACC 2026.
📌 Watch the full interview and follow SOLACI’s coverage at ACC 2026.
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology
, investigador principal del estudio, dialogó en exclusiva con SOLACI sobre los resultados, el alcance y las implicancias clínicas de esta investigación.){kind=link}